Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 1001 - 1010 of 1165

Metadol-D (methadone hydrochloride)

Status:

Concluded with an LOI

Manufacturer:

Paladin Labs Inc.

Indication:

Opioid Dependence

Last updated December 19, 2016

Grastofil (filgrastim)

Status:

Concluded with an LOI

Manufacturer:

ApoPharm Inc.

Indication:

Neutropenia in various indications (Prevention or treatment)

Last updated December 12, 2016

Xolair (omalizumab)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Chronic Idiopathic Urticaria

Last updated November 28, 2016

Orkambi (lumacaftor/ivacaftor)

Status:

Negotiations were not pursued

Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

Indication:

Cystic Fibrosis, F508del CFTR mutation

Last updated November 22, 2016

Inflectra (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Hospira Healthcare Corporation

Indication:

Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and Ulcerative Colitis

Last updated October 31, 2016

Cyramza (ramucirumab)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Last updated October 27, 2016

Yondelis (trabectedin)

Status:

Negotiations were not pursued

Manufacturer:

Janssen Inc.

Indication:

Metastatic Liposarcoma or Leiomyosarcoma

Last updated October 14, 2016

Egrifta (tesamorelin)

Status:

Negotiations were not pursued

Manufacturer:

Theratechnologies Inc.

Indication:

Lipodystrophy, HIV-infected patients

Last updated October 14, 2016

Forxiga (dapagliflozin)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated October 3, 2016

Replagal (agalsidase alfa)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Fabry Disease

Last updated October 1, 2016